Socioeconomic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study
- Published on 08/30/2024
- Reading time: 2 min.
Viktoria Papp1, Malthe Wandall-Holm2, Kristina Bacher Svendsen3, Jette Frederiksen4, Finn Sellebjerg4, Zsolt Illes1, Melinda Magyari2,4
1Department of Neurology, Odense University Hospital, Odense, Denmark
2Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Glostrup, Copenhagen, Denmark
3Neurology, Aarhus University Hospital, Aarhus C, Denmark
4Department of Neurology, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Glostrup, Copenhagen, Denmark
Correspondence to Dr Viktoria Papp; papp.vittoria@gmail.com
Abstract
Background AQP4-antibody seropositive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) may cause reduced work capability due to disability. Here, we evaluated the socioeconomic status of patients with AQP4-Ab+NMOSD in off-label therapy era compared with the general population.
Methods A longitudinal nationwide population-based study including all Danish patients with AQP4-Ab+NMOSD and matched controls from the general population. The cohort was...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Rare Diseases
Receive our newsletter to stay up to date with the latest news in Rare Diseases